Use of SGLT2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease-A Multi-Country Report from the FOUNTAIN Platform

被引：0

作者：

Johannes, Catherine B. ^{[1
]}

Ziemiecki, Ryan ^{[1
]}

Pladevall-Vila, Manel ^{[1
]}

Kosvesdy, Csaba P. ^{[2
]}

Ebert, Natalie ^{[3
]}

Thomsen, Reimar W. W. ^{[4
,5
]}

Christiansen, Christian Fynbo ^{[4
,5
]}

Baak, Brenda ^{[6
]}

Robles Cabaninas, Celia ^{[7
]}

Kashihara, Naoki ^{[8
]}

Yano, Yuichiro ^{[9
]}

Kanegae, Hiroshi ^{[10
]}

Coleman, Craig I. ^{[11
]}

Okami, Suguru ^{[12
]}

Liu, Fangfang ^{[13
]}

Layton, J. Bradley ^{[1
]}

Vizcaya, David ^{[13
]}

Oberprieler, Nikolaus G. ^{[13
]}

机构：

[1] Res Triangle Inst Hlth Solut, Res Triangle Pk, NC USA

[2] Univ Tennessee, Hlth Sci Ctr, Knoxville, TN USA

[3] Charite Univ Med Berlin, Inst Publ Hlth, Berlin, Germany

[4] Aarhus Univ, Dept Clin Epidemiol, Aarhus, Denmark

[5] Aarhus Univ Hosp, Aarhus, Denmark

[6] PHARMO Inst Drug Outcomes Res, Utrecht, Netherlands

[7] FISABIO, Valencia, Spain

[8] Kawasaki Med Sch, Kurashiki, Okayama, Japan

[9] Juntendo Univ, Fac Med, Tokyo, Japan

[10] Genki Plaza Med Ctr Hlth Care, Tokyo, Japan

[11] Univ Connecticut, Storrs, CT USA

[12] Bayer Yakuhin Ltd, Osaka, Japan

[13] Bayer AG, Leverkusen, Germany

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

568

引用

页码：237 / 238

页数：2

共 50 条

[31] Reducing Kidney Disease Burden in Type 2 Diabetes with SGLT2 Inhibitors Shifting the Goalposts Upstream
Rangaswami, Janani
Mathew, Roy O.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (09): : 1119 - 1121
[32] A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand
Chitpim, Natthakan
Leelahavarong, Pattara
Prawjaeng, Juthamas
Ittiphisit, Sakditat
Srinonprasert, Varalak
Kongmalai, Tanawan
SCIENTIFIC REPORTS, 2025, 15 (01):
[33] Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes
Mannucci, Edoardo
Mangia, Pier Paolo
Pradelli, Lorenzo
FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2020, 21 : 3 - 20
[34] Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease
Cheng, Judy W. M.
Colucci, Vincent
Kalus, James S.
Spinler, Sarah A.
ANNALS OF PHARMACOTHERAPY, 2021, 55 (02) : 252 - 260
[35] The extent of use of SGLT2 inhibitors in patients with type 2 diabetes in clinical practice: A study from India
Gokalani, Rutul
Panchal, Dharmendra
Saboo, Banshi
Zinzuwadia, Padmanabh
Patel, Dishank
Chaudhury, Rupam
Chavda, Vipul
Phatak, Sanjeev
Prasad, Renuka
Dariya, S. S.
Shnakar, Arun
Prajapati, Ajay
Chudasama, Dipak
Patel, Nitesh
JOURNAL OF DIABETOLOGY, 2021, 12 (03) : 305 - 309
[36] SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
Davidson, Jaime A.
POSTGRADUATE MEDICINE, 2019, 131 (04) : 251 - 260
[37] Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: An opportunity for pharmacists
Neumiller, Joshua J.
Shubrook, Jay H.
Manley, Tom
Alicic, Radica Z.
Tuttle, Katherine R.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (01) : E65 - E70
[38] Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Beatrice C. Lupsa
Silvio E. Inzucchi
Diabetologia, 2018, 61 : 2118 - 2125
[39] Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Lupsa, Beatrice C.
Inzucchi, Silvio E.
DIABETOLOGIA, 2018, 61 (10) : 2118 - 2125
[40] SGLT2 Inhibitors slow down the Progression of chronic Kidney Disease
不详
NEPHROLOGE, 2019, 14 (03): : 225 - 225

← 1 2 3 4 5 →